Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (8), the stock would be worth ¥15.5 (44% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.2 | ¥27.69 |
0%
|
| 3-Year Average | 8 | ¥15.5 |
-44%
|
| 5-Year Average | 8.1 | ¥15.77 |
-43%
|
| Industry Average | 30.7 | ¥59.82 |
+116%
|
| Country Average | 28.8 | ¥56.12 |
+103%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
|
25.5B CNY | 14.2 | 14.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 153.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 35.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 24.5 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 12 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Hubei Jumpcan Pharmaceutical Co Ltd
Glance View
In the bustling landscape of China's pharmaceutical industry, Hubei Jumpcan Pharmaceutical Co Ltd stands as a key player, weaving together tradition and modernity. Founded in 1951, this company has curated a journey of evolution—from its roots in the rich tapestry of traditional Chinese medicine to its current standing as a significant contributor to the healthcare sector. Core to Jumpcan's operation is its production and distribution of a diverse array of pharmaceutical products that span across various therapeutic areas, including digestive health, dermatology, and respiratory care. With an adept focus on over-the-counter medications and prescription drugs, Jumpcan effectively meets the health needs of a broad demographic, leveraging both the enduring appeal of traditional remedies and the growing demand for contemporary medical solutions. The business prowess of Jumpcan is deeply entwined with its strategy of innovation and adherence to quality standards, ensuring its pharmaceutical offerings are not only effective but also safe for consumption. Anchored in robust R&D initiatives, the company continues to enhance its product line, incorporating advanced technology and scientific research to produce medicines that align with global quality benchmarks. Furthermore, Jumpcan thrives on an extensive distribution network that spans across China, ensuring widespread accessibility of its products. By maintaining a keen understanding of the market dynamics and consumer preferences, Jumpcan artfully aligns its operations to capitalize on both domestic and international opportunities, thus solidifying its financial standing and perpetuating its growth within the dynamic corridors of the pharmaceutical industry.